Real-time Multi-Cancer Early Risk Assessment
Understand what’s happening inside your body today. Our blood-based test analyzes molecular patterns linked to common solid tumours, offering a meaningful early look at your current cancer risk — before conventional screening may detect changes.
Why It Matters
- More than 1 in 3 Canadians will develop cancer in their lifetime.
- About 1 in 4 Canadians die from cancer.
- Standard screening programs only cover a few cancers and apply to limited age or risk groups.
This leaves a major gap: most cancers are found too late, when treatment options are fewer and outcomes are worse.
The miRoncol Real-time Multi-Cancer Early Risk Assessment helps fill that gap. By analyzing microRNA patterns associated with cancer biology, the test offers a molecular-level snapshot of your current cancer risk.
How It Works
Our approach integrates biology and advanced data science:
MicroRNA biomarkers
Sensitive signals of early cancer-related cellular change
AI-based recognition
Identifies shared molecular patterns across cancers, trained on human data
Studies
Built on more than 11,000 samples with specificity above 99% and sensitivity above 90% for many common cancers
The result: meaningful insight into your current biological signals, designed to support earlier conversations with your physician.
Cancers Covered
The test is designed to identify molecular patterns linked to more than a dozen common solid tumours, including:
- Lung
- Colorectal
- Prostate
- Pancreatic
- Gastric
- Ovarian
- Liver & biliary tract
- Bladder
- Sarcoma
- Glioma
Together, these cancers represent the majority of cases that impact Canadians today.
Who It’s For
The test is best suited for proactive, health-conscious individuals who:
- Want to add molecular insight to their annual checkups or wellness assessments
- Have extended lifestyle or environmental exposures known to influence cancer risk
- Are investing in executive health or integrative medicine programs
- Have a family history of cancer and want real-time insight beyond genetic predisposition
How It Works
Our approach integrates biology and advanced data science:
Benefits
- Provides a real-time snapshot of your current cancer risk
- Covers a broad range of common solid tumours
- Supports meaningful conversations with your physician
- Complements existing screening program
Limitations & Ethics
This is an early risk assessment, not a diagnostic test. Results are designed to complement, not replace, physician-led evaluation and conventional screening programs.
Next Step
The miRoncol Real-time Multi-Cancer Early Risk Assessment helps you see what’s happening inside your body today so you and your physician can decide if earlier follow-up is appropriate.
